PrEParing for choice in a new era of HIV prevention
- PMID: 37898147
- PMCID: PMC11156182
- DOI: 10.1016/S2352-3018(23)00263-1
PrEParing for choice in a new era of HIV prevention
Conflict of interest statement
LAG is supported by the National Institutes of Health (NIH) through grant T32 AI007001. BHC is supported by NIH grants R01 AI131060 and R01 AI157859. We declare no competing interests.
Comment on
-
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.Lancet HIV. 2023 Dec;10(12):e779-e789. doi: 10.1016/S2352-3018(23)00227-8. Epub 2023 Oct 25. Lancet HIV. 2023. PMID: 37898146 Free PMC article. Clinical Trial.
References
-
- Celum C, Nair G, Szydlo D, Brown ER. Adherence, safety and choice of the dapivirine vaginal ring and oral emtricitabinetenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: A randomized crossover trial. Lancet HIV 2023. (Accepted for publication) - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical